Combination Products Regulatory Consulting Services

Combination products are therapeutic or diagnostic products that combine two or more regulated components, such as a drug and device, biologic and device, or all three. Regulatory requirements depend on the product’s primary mode of action, intended use, technical design, and market pathway. Proper classification is critical because it affects submission strategy, testing expectations, labeling, quality system obligations, and post-market responsibilities.

The pathway is determined by evaluating the product’s primary mode of action, constituent parts, intended use, claims, risk profile, and target markets. Consultants review whether the lead framework is device, drug, or biologic driven, then map the submission route, supporting evidence, quality requirements, and authority interactions. This early strategy work helps avoid misclassification, incomplete submissions, and unnecessary delays during review.

Most combination product submissions require a coordinated package that may include device technical documentation, risk management files, design records, clinical or performance evidence, labeling, manufacturing information, quality system documentation, and constituent-part data. The exact structure depends on the jurisdiction and pathway. Strong submissions also show traceability across claims, testing, risk controls, and intended use so reviewers can assess the product without ambiguity.

Yes. Elexes provides pre-submission support that includes pathway analysis, readiness assessments, mock meetings, regulatory strategy development, and documentation review before formal filing. This helps identify missing evidence, weak claims alignment, quality system gaps, and testing deficiencies early. Addressing those issues before submission reduces the likelihood of deficiency letters, repeated review cycles, and costly timeline disruptions.

Yes. Elexes supports manufacturers in responding to FDA and other regulatory authority inquiries, deficiency letters, and formal actions. The work typically includes analyzing each question, identifying the underlying documentation or evidence gap, coordinating technical inputs, and drafting structured responses that directly address reviewer concerns. A disciplined response strategy can reduce follow-up rounds and improve the chances of keeping the review process moving.

Yes. Elexes supports global regulatory strategy across markets including the USA, Canada, Europe, Australia, the UK, and other regions. For combination products, this means aligning documentation and evidence to different authority expectations while avoiding unnecessary duplication. The team helps manufacturers sequence submissions, adapt technical files, manage market-specific compliance requirements, and maintain consistency across international regulatory programs.

Yes. Combination product compliance continues after authorization through change assessments, complaint handling, post-market surveillance, reportability, document control, and quality system governance. Elexes offers outsourced and virtual RAQA support to help manufacturers manage these ongoing obligations without building a full in-house team. This model is especially useful for growing companies with active portfolios and limited internal bandwidth.

Combination products often fail or stall in review because documentation is incomplete, evidence is not well integrated, or quality and risk files do not support the proposed claims. A submission readiness assessment provides an expert review of the package against the intended pathway and authority expectations. The result is a prioritized action plan that helps teams fix critical gaps before submission and defend the file more confidently.